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Background
Duchenne (DMD) and Becker (BMD) muscular dystrophies
( MD) are inherited X-linked diseases characterized by
absence or decrease of dystrophin, a sarcolemal protein
that is essential for maintenance of the muscular mem-
brane integrity during muscular contraction. Cardiac invol-
vement is as high, it can be clinically silent, but is often
complicated by severe heart failure and high mortality.
Angiotensin-converting enzyme inhibitors (ACEI) is
recommended for patients with left ventricular dysfunction.
We previously described that CMR can identify myocardial
fibrosis (MF) even in the early stages of cardiomyopathy in
MD before overt LV dysfunction (J Am Coll Cardiol
2007;49:1874-9). The impact of treatment with ACE inhibi-
tors in the progression of fibrosis in patients with MD and
preserved LV function is still unknown.
Methods
We enrolled 76 pts, 70 pts with DMD and 6 BMD. Mean
age was 13.1 ± 4.4 years. All patients underwent baseline
and 2.3 years follow-up CMRs, using cine resonance for
function evaluation and myocardial delayed enhancement
(MDE) technique for MF detection. Forty-two pts with
MF and normal LVEF were randomized into 2 groups, for
receiving or not ACEI. CMR were performed on a 1.5-T
Siemens Avanto (Erlangen, Germany). Two experienced
observers measured LV volumes, ejection fraction and MF
mass (5 standard deviation thresholding, on CMR42,
v.3.4.2 Circle CVI, Calgary, Alberta, Canada). Wilcoxon
test was used for comparison of MF between baseline and
follow-up.
Results
Two patients died before follow-up CMR. For all
74 patients, MF increased significantly from 20.8 ±
17.3 % to 26.6 ± 18.7 % on the follow-up, p < 0,001. In a
sub-group with LV dysfunction at baseline (n = 11) MF
increased from 31.6 ± 9.6 % to 40.6 ± 9.4 %, p = 0.013.
Patients with MF and preserved LVEF that were rando-
mized for treating with ACEI had lower evolution of MF
than those who were randomized to untreated group (3.1
± 7.4% vs. 10.0 ± 6.2%, respectively, p = 0.001). Lower
progression of MF was also noted when comparing the
two treated groups (LV dysfunction and normal LV func-
tion randomized to treated), 9.0 ± 9.9 % vs. 3.1 ± 7.4 %,
p = 0,047, respectively. Using multivariate regression ana-
lysis, we found that belonging to the ACEI treated group
decreases the progression of MF even after adjusting for
age, creatine kinase level and baseline MF, p = 0.039) and
indicated a trend for lower probability of presenting
LVEF < 50% at follow-up CMR (OR = 3.18, p = 0.102, by
logistic regression).
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Conclusions
Myocardial fibrosis, detected by CMR, progressively
increases in all patients with Duchenne and Becker mus-
cular dystrophy over a period of 2.3 years. In patients with
MF and preserved LVEF, the treatment with ACEI
decreases the progression of MF. Patients with LV dys-
function at baseline show progression of MF despite of
ACEI therapy. Our data suggest that early initiation of
ACEI therapy, before LV dysfunction can be detected, can
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Figure 1 Myocardial Fibrosis Progression in DMD and Becker
pts over a period of 2.3 years. SD Group - group with systolic
dysfunction WSDF-T group - group without systolic dysfunction and
with fibrosis, treated with ACEI WSDF-WT group - group without
systolic dysfunction and with fibrosis, without treatment.
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